ArticleGenes & development2018
Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.
Abstract read
In one paragraph
Article in Genes & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.BMC medical genetics · 2020Pooled it
- An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy.Cancer research · 2025Trial
- Molecular regulation of PGC-1α: from protein-protein interactions and post-translational modifications to pharmacological modulation.Journal of molecular medicine (Berlin, Germany) · 2026Review
- New cell lines expanding the diversity of Ewing sarcoma models.International journal of cancer · 2026Article
- Identification of Somatic and Germline Mutations Influencing Treatment Outcomes and Disease Susceptibility in Tunisian Triple-Negative Breast Cancer Using Next-Generation Sequencing.British journal of biomedical science · 2026Article
- The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Semiquantitative immunohistochemical (IHC) pixelwise H-score of mitochondrial transcription factor A (TFAM) in gastric adenocarcinoma (GAC): clinicopathological significance and association with p53 and HER2.World journal of surgical oncology · 2025Article
- Article
- Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, mJournal of advanced research · 2025Review
- Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.Discover oncology · 2025Article
- TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A.Blood advances · 2025Article
- Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer.Frontiers in immunology · 2025Review
- From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.Biomarker research · 2024Review
- Article
- Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.Cancer communications (London, England) · 2024Review
- Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases.Signal transduction and targeted therapy · 2024Review
- Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures, and serum samples from a Spanish Caucasian population.Frontiers in oncology · 2024Article
- From metabolism to malignancy: the multifaceted role of PGC1α in cancer.Frontiers in oncology · 2024Review
- The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention.Cancers · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Subhasree BasuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Keerthana Gnanapradeepan *Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Thibaut Barnoud *Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Che-Pei Kung *Program in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Michele TavecchioProgram in Tumor Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Jeremy ScottProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Andrea WattersProgram in Tumor Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Qing ChenProgram in Tumor Microenvironment and Metastasis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Andrew V KossenkovProgram in Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Dario C Altieri · 1985 to 2026
$75.9MTRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3MFunctional Analysis of p53 Polymorphic Variants - Diversity SupplementR01CA102184 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2005 to 2026
$7.4Mp53 Variants in Cancer Risk and TherapyR01CA201430 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2016 to 2020
$2.2MAdvancing Cancer Research through Comprehensive Proteomics and Metabolomics AnalysesR50CA221838 · NCI · WISTAR INSTITUTE · PI Hsin-Yao Tang · 2017 to 2026
$2.1MIntegrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6MJuxtacrine regulation of metastasis from brain microenvironmentsK22CA181470 · NCI · WISTAR INSTITUTE · PI CHEN, QING · 2015 to 2017
$588kPurchase of a PerkinElmer IVIS SpectrumCT Imaging SystemS10OD021669 · OD · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2017 to 2017
$579kPurchase of a Seahorse Bioscience XF AnalyzerS10OD023658 · OD · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2017 to 2017
$188kNCI NIH HHS K22 CA181470NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA102184NCI NIH HHS R01 CA201430NCI NIH HHS R50 CA211199NCI NIH HHS R50 CA221838NCI NIH HHS T32 CA009171NIH HHS S10 OD021669NIH HHS S10 OD023658
Abstract
Mutant forms of p53 protein often possess protumorigenic functions, conferring increased survival and migration to tumor cells via their "gain-of-function" activity. Whether and how a common polymorphism in
Indexed as
Genes, p53MutationAnimalsBreast NeoplasmsCell Line, TumorCell MovementFemaleHepatocyte Nuclear Factor 4HumansMaleMiceNeoplasm InvasivenessNeoplasm MetastasisNeoplasmsOxidative PhosphorylationPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaHepatocyte Nuclear Factor 4HNF4A protein, humanPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphacodon 72metastasismutant p53oxidative phosphorylationPGC-1α
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.